title: Amyloid and Tau Biomarkers in Subjective Cognitive Impairment.
abstract: Subjective cognitive impairment (SCI) refers to concerns regarding one's cognitive functioning in the absence of objective evidence of impairment, and may represent an early stage of Alzheimer's disease. However, as not all individuals with SCI cognitively decline, there is growing interest in the early identification of those individuals with SCI who are most at risk of developing Alzheimer's disease. One promising method of early identification involves the use of biomarkers that are known to be associated with the pathophysiology of the disease; in particular, markers of amyloid and tau accumulation. While there has been substantial research on amyloid and tau biomarkers in the context of mild cognitive impairment (MCI), only recently has attention shifted to SCI, which may represent an even earlier stage in the disease course. The purpose of this paper is to qualitatively review the literature on amyloid and tau biomarkers in SCI. A brief discussion of non-amyloid/tau biomarkers is also included. Not surprisingly, we found that amyloid and tau biomarker profiles become increasingly abnormal from SCI, to MCI, to Alzheimer's disease. Additionally, although amyloid and tau biomarkers appear to be unable to differentiate between SCI and healthy controls, there is some evidence to suggest that they may be able to differentiate between those individuals with SCI who cognitively decline over time and those who do not. While this finding has potential clinical implications, achieving optimal predictive value will likely require further research into the use of numerous biomarkers in combination.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Colijn
authors.forename: George T
authors.initials: GT
authors.lastname: Grossberg
mesh_terms: D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds / Q000493:pharmacokinetics; D015415:Biomarkers / Q000378:metabolism; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging / Q000378:metabolism*; D003430:Cross-Sectional Studies; D016206:Databases, Bibliographic; D006801:Humans; D008137:Longitudinal Studies; D049268:Positron-Emission Tomography; D013844:Thiazoles / Q000493:pharmacokinetics; D016875:tau Proteins / Q000378:metabolism*
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D015415:Biomarkers; D013844:Thiazoles; D016875:tau Proteins
keywords: Alzheimer’s disease; Pittsburgh compound B; amyloid; biological markers; dementia; mild cognitive impairment; positron emission tomography; prodromal symptoms; tau proteins; tauopathies